4basebio (LON:4BB) Shares Down 2% - Here's What Happened

On Wednesday, shares of 4basebio PLC (LON:4BB) experienced a decline of 2% during mid-day trading, dropping to a low of GBX 1,200 ($15.31). The shares were last traded at the same price of GBX 1,200 ($15.31). In total, approximately 3,555 shares changed hands, reflecting a decrease of 19% compared to the average trading session volume of 4,376 shares. Previously, the stock had closed at GBX 1,225 ($15.63).

4basebio Trading Down 2.0%

The company's current market capitalization stands at £153.72 million. It has a P/E ratio of -1,538.46 and a beta of 1.09. Additionally, its debt-to-equity ratio is notably high at 201.47. The company's quick ratio is 3.52, and the current ratio is 2.73. The 50-day moving average for the stock is GBX 1,301.31, while the 200-day moving average is GBX 1,412.

Insider Activity

In recent insider news, Heikki Lanckriet, a company insider, purchased 46,500 shares of the stock on November 15th. The shares were bought at an average price of GBX 1,325 ($16.90) each, totaling £616,125 ($785,973.98). Notably, company insiders collectively own 68.44% of 4basebio's stock.

About 4basebio

4basebio PLC is involved in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, as well as targeted non-viral vector solutions, primarily within the United States, Europe, and on a global scale. The company also provides services for AVV and Lentivirus manufacturing, which are critical for gene therapies and vaccine developments.

Investment Consideration

Before deciding on an investment in 4basebio, it may be wise to consider recent market analyses. Although the stock holds a "Hold" rating among analysts, there are recommendations for five alternative stocks that analysts believe may offer better investment opportunities. Investors are encouraged to conduct thorough research before making investment decisions.

4basebio, stocks, trading